Oric Pharma Initiates Phase 3 Himalayas-1 Trial for mCRPC

Oric Pharmaceuticals initiated the global Phase 3 Himalayas-1 registrational trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with abiraterone. The company also announced a clinical trial collaboration and supply agreement with Bayer, where Bayer will provide darolutamide for the trial at no cost. The Himalayas-1 trial is expected to enroll approximately 600 patients across 25 countries, with radiographic progression-free survival as the primary endpoint. Oric retains full global development and commercial rights to rinzimetostat.